NeuroTimone Facility (PFNT)

The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.


  1. Michel Khrestchatisky gives a talk at the « Nanomedicine for treating cancer and brain diseases » symposium
  2. Yvon Berland mentions Vect-Horus as one of the three 3 AMU biotech success stories

    In an interview published by "La Provence" on November 30, 2018 Yvon Bertrand, President of Aix-Marseille University, explains that AMU is very proud of its contribution to the field of Artificial Intelligence but also to the development of companies such as "First Light Imaging", VECT-HORUS or Innate-Pharma. They are real success stories from public research.

  3. INP Team 9 participated in a joint review on Tau molecular structures
  4. New article of the cytoskeleton and neurophysiopathology team

    The last work of team 9 "Tau regulates the microtubule-dependent migration of glioblastoma cells via Rho-ROCK signaling pathway" is now published in J. cell. Science. This work identifies for the first time the role and mechanisms implicating the tau protein in the invasion processes of glioblastomas, very aggressive brain tumors. This work highlights the role of the Tau protein as a common target between cancers and neurodegeneration.

  5. Hervé Kovacic elected president of the CNU section 85

    Professor of Biophysics and Biomathematics at the Faculty of Pharmacy of Marseille, Hervé Kovacic is elected for a six-year term. Section CNU 85 manages the qualifications, promotions and bonuses of teacher-researchers specializing in physicochemical sciences and applied engineering in health. Doctor Pascale Barbier, also from team 9 of INP has been nominated as a member of the same CNU section.

  6. Jean-Michel Paumier successfully defended his doctoral thesis

    Jean-Michel Paumier, former PhD student in Team 1 (Neural Plasticity and Degeneration), has successfuly defended his thesis on Wednesday the 05th of December 2018. After few hours of a nice presentation followed by many questions, the examining board congratulated Jean-Michel for his good work and granted him the diploma of doctor in Neuroscience.

  7. 3 PhD students of the INP participate in the Neuroschool PhD Days 2018

    On December 6 and 7, 2018, Neuroschool PhD Days took place. In this edition entitled "Through the looking glass: beyond our reality", second-year neuroscience PhD students  were invited to present their work.

    It is in this context that the 3 PhD students of the INP took part: Laurie Arnaud, Audrey Jacq and Dominika Pilat.

  8. Vect-Horus announces agreement with Johnson & Johnson innovation

    Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The goal of this collaboration is to use Vect-Horus’ proprietary technology to transport various Janssen monoclonal antibodies to the brain for the treatment of neurodegenerative diseases. This deal was facilitated by Johnson & Johnson Innovation Limited.


INP in numbers

  • 126 members
  • 44 researchers
  • 48 research assistants
  • 12 post-docs
  • 11 PhD


New publication from the GlioME Team and the national POLA network (dedicated to high grade oligodendroglioma) pointing at CDKN2A homozygous deletion as a strong adverse prognostic factor in diffuse malignant IDH-mutant gliomas.

In a large cohort of 911 high-grade IDH-mutant gliomas from the French national POLA network, we investigated the prognostic value of the CDKN2A gene homozygous deletion as well as WHO grading criteria (mitoses, microvascular proliferation, and necrosis).

We showed that:
- CDKN2A homozygous deletion characterizes diffuse malignant IDH-mutant gliomas with worst outcome.

- Microvascular proliferation stratifies IDH-mutant gliomas lacking CDKN2A homozygous deletion.


Michel KHRESTCHATISKY invited to the third edition of “Translational neuroscience Day: challenges and opportunities” co-organized by DHUNE and NeurATRIS

Michel KHRESTCHATISKY, Director of the UMR7051 Institute of Neurophysiopathology at Aix-Marseille University / CNRS and co-founder of VECT-HORUS was invited at the third edition of Translational neuroscience Day: challenges and opportunities” co-organized by DHUNE and NeurATRIS and hosted by BioFIT on December 10, 2019 (


New publication for the Neuro-inflammation and Multiple Sclerosis team (INP team 5) in Cytokine about the immunomonitoring of infliximab biotherapies

In this paper, Daniel Bertin evaluated the immunological follow-up of patients suffering from chronic inflammatory diseases and receiving anti-TNF biotherapy. Three commercial ELISA assays for monitoring soluble through levels of infliximab and anti-infliximab antibodies in serum showed a good global correlation of results. However, some quantitative discrepancies could change clinical decision. As a consequence, Daniel Bertin recommended to keep the same kit to perform a longitudinal follow-up of patients.


Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response" .

Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, in the Insitute of NeuroPhysiopathology, UMR CNRS 7051, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response".

Subsequently she was interviewed by :
France 3  (JT 19/20 PACA diffusion du 15/11: 7'09 à 9'45) ; 
Provence Azur (18/11/2019) ;
20 Minutes Marseille (18/11/2019)
- La Provence



GlioME team in collaboration with INT (Institute of Neurosciences Timone) published a new study in Journal of Neuroinflammation on the effect of Bevacizumab on glioblastoma-bearing mice, using 2-photon imaging

Our data show that VEGF blockade leads to an increased recruitment of monocytes and to an adjustment of dendritic cell subsets’ profiles, differing in their ability to induce an adaptive immune response. Altogether, they provide important new insights into the effects of Bevacizumab at the cellular level and into the spatio-temporal evolution of intra-tumoral innate immune cell densities.